Posttherapy radiation safety considerations in radiomicrosphere treatment with 90Y-microspheres
- PMID: 18006608
- DOI: 10.2967/jnumed.107.045443
Posttherapy radiation safety considerations in radiomicrosphere treatment with 90Y-microspheres
Abstract
Radiomicrosphere treatment involves the intrahepatic arterial administration of (90)Y-resin or (90)Y-glass microspheres. The microspheres are biocompatible, but not biodegradable, and little to no (90)Y leaches from the microspheres. Without any bioelimination, the beta-dose delivery is generally confined to the liver. Although U.S. Nuclear Regulatory Commission requirements permit patients treated with these microspheres to be released without the need for dose determination or patient instructions, there are important radiation safety issues that need scientific clarification. We carefully evaluated the radiation exposure mechanisms, including the bremsstrahlung radiation doses to others, for a variety of lifestyle behaviors. Dose estimates were also made for several practical and theoretic situations involving the patient's gonads, an embryo or fetus, and a nursing infant. For the infant, we evaluated the potential beta-dose that might be introduced via breast milk ingestion. The bremsstrahlung component of the decay scheme of the pure beta-emitter (90)Y has traditionally been ignored in internal and external dose calculations. Because the production of in vivo bremsstrahlung with the high-energy pure beta-particle-emitting radionuclides used for therapeutic purposes is sufficient to permit external detection and imaging, we believe that the contribution of such radiation should be considered with regard to patient release; we therefore chose to evaluate this potential external radiation hazard. In all cases, the estimated doses were very small, indicating that no patient restrictions are required for radiation safety purposes after the release of a patient who has been treated with (90)Y-microspheres.
Similar articles
-
Radiation emission from patients treated with selective hepatic radioembolization using yttrium-90 microspheres: are contact restrictions necessary?J Vasc Interv Radiol. 2012 May;23(5):661-7. doi: 10.1016/j.jvir.2012.01.070. Epub 2012 Mar 21. J Vasc Interv Radiol. 2012. PMID: 22440592
-
Treatment of hepatocellular carcinoma by radioembolization using 90Y microspheres.Dig Dis. 2009;27(2):164-9. doi: 10.1159/000218349. Epub 2009 Jun 22. Dig Dis. 2009. PMID: 19546555 Review.
-
Biokinetic and dosimetric modelling in the estimation of radiation risks from internal emitters.J Radiol Prot. 2009 Jun;29(2A):A81-A105. doi: 10.1088/0952-4746/29/2A/S06. Epub 2009 May 19. J Radiol Prot. 2009. PMID: 19454809 Review.
-
Bremsstrahlung radiation exposure from pure beta-ray emitters.J Nucl Med. 1999 Jun;40(6):1024-8. J Nucl Med. 1999. PMID: 10452321
-
Bremsstrahlung radiation dose in yttrium-90 therapy applications.J Nucl Med. 1994 Aug;35(8):1377-80. J Nucl Med. 1994. PMID: 8046497
Cited by
-
AAPM Medical Physics Practice Guideline 14.a: Yttrium-90 microsphere radioembolization.J Appl Clin Med Phys. 2024 Feb;25(2):e14157. doi: 10.1002/acm2.14157. Epub 2023 Oct 11. J Appl Clin Med Phys. 2024. PMID: 37820316 Free PMC article.
-
The American Brachytherapy Society consensus statement for permanent implant brachytherapy using Yttrium-90 microsphere radioembolization for liver tumors.Brachytherapy. 2022 Sep-Oct;21(5):569-591. doi: 10.1016/j.brachy.2022.04.004. Epub 2022 May 20. Brachytherapy. 2022. PMID: 35599080 Free PMC article.
-
Personnel dose reduction in 90Y microspheres liver-directed radioembolization: from interventional radiology suite to patient ward.Br J Radiol. 2017 Mar;90(1071):20160591. doi: 10.1259/bjr.20160591. Epub 2016 Dec 20. Br J Radiol. 2017. PMID: 27993095 Free PMC article.
-
A review of 3D image-based dosimetry, technical considerations and emerging perspectives in 90Y microsphere therapy.J Diagn Imaging Ther. 2015;2(2):1-34. doi: 10.17229/jdit.2015-0428-016. Epub 2015 Apr 28. J Diagn Imaging Ther. 2015. PMID: 27182449 Free PMC article.
-
Proliferative and Glycolytic Assessment of the Whole-Body Bone Marrow Compartment.Mol Imaging Radionucl Ther. 2015 Jun 5;24(2):71-9. doi: 10.4274/mirt.22931. Mol Imaging Radionucl Ther. 2015. PMID: 26316472 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources